Medtronic Plc Hits New 52-Week Low at USD 78.91

Medtronic Plc, a prominent player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 78.91 as of April 29, 2026. This decline marks a significant shift for the company, which has experienced a 1-year performance drop of 4.53%, contrasting sharply with the S&P 500's impressive gain of 28.33% during the same period. With a market capitalization of USD 113,290 million, Medtronic operates within a competitive landscape, characterized by a price-to-earnings (P/E) ratio of 20.00. The company maintains a dividend yield of 3.20%, reflecting its commitment to returning value to shareholders. However, its return on equity stands at 0.00%, indicating challenges in generating profit from shareholder equity. Despite the recent price movement, Medtronic's financial metrics reveal a low debt-to-equity ratio of 0.43, suggesting a conservative approach to leverage. The company has shown resilience with a robust operating cash flow of USD 7,146 million reported in July, alongside a return on capital employed (ROCE) of 9.72%. As institutional holdings remain high at 86.93%, the stock's current valuation may attract attention as it trades at a discount compared to historical averages.